Surotomycin (a novel cyclic lipopeptide) vs Vancomycin for treatment of Clostridioides difficile infection: A systematic review and Meta-analysis.
Current guidelines recommend the use of vancomycin for the initial treatment of moderate to severe Clostridioides difficile infection (CDI). Surotomycin, a novel antibiotic, has been utilized for the management of CDI with variable results. A systematic literature search was performed using the following electronic databases [Medline, embase, google scholar and Cochrane] for eligible studies. Randomized controlled trials comparing Surotomycin with Vancomycin for the CDI treatment were included. Demographic variables and outcomes (CDI resolution, CDI recurrence, B1/NAP1/027-specific strain treatment, B1/NAP1/027-strain recurrence, death not related to treatment) were analyzed. The primary outcome was clinical cure rate defined as resolution of CDI at the end of 10-day drug course. Three RCTs met the inclusion criteria with a total of 1280 patients with CDI who received either surotomycin 250 mg twice daily (642 patients) or vancomycin 125 mg four times daily (638 patients). Clinical cure rates after 10 days of treatment with either surotomycin or vancomycin were not significantly different (pooled OR: 0.89, 95% CI 0.66-1.18, p=0.41). Sustained clinical response at clinical follow-up and the overall recurrence of CDI were also not significantly different between the two groups - pooled OR 1.15 (95% CI 0.89-1.50, p=0.29) and pooled OR 0.74 (95%CI 0.52-1.04, p=0.08), respectively. With regards to the NAP1/BI/027 strain, patients in the surotomycin group had significantly lower rates of recurrence compared to vancomycin (pooled OR 0.35, 95% CI 0.19-0.63, p<0.01). Surotomycin is non-inferior to vancomycin and offers a promising alternative for the treatment and prevention of C. diff infection. .